Evenamide is under clinical development by Newron Pharmaceuticals and currently in Phase III for Schizophrenia. According to GlobalData, Phase III drugs for Schizophrenia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Evenamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evenamide overview
Evenamide (NW-3509) is under development for the treatment of chronic schizophrenia. The drug candidate is a new chemical entity and administered orally as a capsule. The drug candidate acts by targeting voltage gated sodium channel including Nav 1.3, 1.7, 1.8.
Newron Pharmaceuticals overview
Newron Pharmaceuticals (Newron) is a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson’s disease. Newton’s other products in the pipeline include ralfinamide for neuropathic pain; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. The company has an international presence, with products approved in countries including Switzerland, the US, Australia, Canada, and Japan. Newron is headquartered in Bresso, Milan, Italy.
For a complete picture of Evenamide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
